{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"}],"units":"Participants"}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"}],"units":"Participants"}],"title":"C1D22"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"title":"C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"}],"units":"Participants"}],"title":"C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"title":"C7D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"C9D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"30 day follow up"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"title":"90 day follow up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"}],"units":"Participants"}],"description":"Immunogenicity will be measured by the number of participants that are ADA positive.","groups":[{"description":"Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\\^2 on C1D1 followed by subsequent doses of 600 mg/m\\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Participants also received up to 12 treatments of 5-fluorouracil, folinic acid and oxaliplatin (mFOLFOX6) (or components of mFOLFOX6 if some components were discontinued due to toxicity) over 4 or more cycles in which mFOLFOX6 was administered on Days 1, 15 and 29 of each cycle (5-fluorouracil administered by IV bolus 400 mg/m\\^2 over 5 to 15 minutes followed by 2400mg/m\\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Folinic acid administered 400 mg/m\\^2 IV infusion over 2 hours; oxaliplatin administered 85 mg/m\\^2 IV infusion over 2 hours). A maximum of 12 doses of oxaliplatin was permitted. After mFOLFOX6 treatments, participants could continue to receive 5-FU and folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.","id":"OG000","title":"mFOLFOX6 + Zolbetuximab"}],"paramType":"NUMBER","populationDescription":"Participants who were randomized to zolbetuximab + mFOLFOX6 Arm with at least One Valid Result for ADA.","reportingStatus":"POSTED","timeFrame":"Predose on C1D1, C1D22, C3D1, C5D1, C7D1, C9D1, 30-day follow up, 90-day follow up","title":"Number of Participants With Anti-drug Antibodies (ADA)","type":"SECONDARY","unitOfMeasure":"Participants"}